Cocrystal Pharma Inc

Cocrystal Pharma, a clinical-stage biotech developing broad-spectrum antivirals, is undergoing a strategic reset that investors may be overlooking, highlighted by the appointment of veteran biotech executive James Sapirstein as CEO and a $5 million investment from OPKO Health. Sapirstein, who has led or participated in 23 product launches and previously served as CEO of Tobira Therapeutics, replaced the co-CEO structure on June 3, 2026, with Sam Lee becoming President and Chief Scientific Officer. The company's chairman, Nobel laureate Roger Kornberg, emphasized that the board had known Sapirstein for years, suggesting a deliberate recruitment. OPKO's investment, led by billionaire Phillip Frost, who is also a Cocrystal co-founder and director, came through a private placement of 5,474,053 shares at $0.9134 per share, with no warrants or derivatives attached. Cocrystal's lead candidate, CDI-988, an oral antiviral for norovirus, has received FDA Fast Track designation and is in a Phase 1b challenge study, with topline data expected late in the fourth quarter of 2026. The company had $2.1 million in cash at the end of Q2, and with the new infusion, has about seven months of runway. Despite a market cap of $21 million and an accumulated deficit of over $347 million, the strategic moves, including a board with deep pharma experience, position the company for potential value creation, though the thesis partly relies on speculation about future acquisitions.

Cocrystal Pharma has secured a $5 million investment from longtime investor OPKO Health through a private placement. Cocrystal sold 5,474,053 shares of its common stock to OPKO at $0.9134 per share, with no warrants or other derivative securities included. The company expects to report topline data from its Phase 1b norovirus trial by the end of the fourth quarter of 2026. OPKO Health Chairman and CEO Dr. Phillip Frost said the additional investment reflects continued conviction in Cocrystal's science and its path forward.